Treatment Outcomes with Hypomethylating Agents and Venetoclax for AML in the Community Compared to an Academic Setting

被引：0
|
作者：
Jeffrey, Lantz, Jr. [1 ]
Pham, Natalie [2 ]
Jones, Caroline [3 ]
Kundu, Debamita [4 ]
McCann, Nicholas [5 ]
El Chaer, Firas [1 ]
Reed, Daniel [1 ]
Keng, Michael [1 ]
机构：
[1] Univ Virginia, Div Hematol & Oncol, Dept Med, Comprehens Canc Ctr,Med Ctr, Charlottesville, VA USA
[2] Univ Virginia, Dept Med, Med Ctr, Charlottesville, VA USA
[3] Univ Virginia, Dept Pharm, Med Ctr, Charlottesville, VA USA
[4] Univ Virginia, Div Biostat, Charlottesville, VA USA
[5] Univ Virginia, Sch Med, Charlottesville, VA USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-190176
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Less is more: An analysis of venetoclax and hypomethylating agent post-induction treatment modifications in AML
    Boisclair, Stephanie
    Zhou, Edward
    Naing, Phyu
    Thakur, Richa
    Jou, Erin
    Goldberg, Bradley
    Gladstone, Douglas E.
    Allen, Steven L.
    Kolitz, Jonathan E.
    Chitty, David W.
    LEUKEMIA RESEARCH, 2024, 143
  • [42] Venetoclax combined with hypomethylating agents and the CAG regimen in relapsed/refractory AML: a single-center clinical trial
    Liu, Yifan
    Li, Yanfen
    Zhang, Ran
    Yu, Zhangyu
    Jing, Yu
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [43] Antibody response to mRNA vaccination for COVID-19 in patients with AML receiving hypomethylating agents alone or with venetoclax
    Candoni, Anna
    Callegari, Chiara
    Zannier, Maria Elena
    Fanin, Renato
    BLOOD ADVANCES, 2022, 6 (10) : 3068 - 3071
  • [44] Venetoclax in Combination with Hypomethylating Agents Induces Rapid, Deep and Durable Responses in Patients with AML Ineligible for Intensive Therapy
    Pollyea, Daniel A.
    Pratz, Keith W.
    Jonas, Brian A.
    Letai, Anthony
    Pullarkat, Vinod A.
    Wei, Andrew
    Konopleva, Marina Y.
    Recher, Christian
    Frankfurt, Olga
    Rizzieri, David
    Xu, Tu
    Dail, Monique
    Chyla, Brenda
    Potluri, Jalaja
    DiNardo, Courtney D.
    BLOOD, 2018, 132
  • [45] Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients
    Christophe Willekens
    Alexandre Bazinet
    Samy Chraibi
    Alex Bataller
    Justine Decroocq
    Naszrin Arani
    Benjamin Carpentier
    Caitlin Rausch
    Delphine Lebon
    Abhishek Maiti
    Nicolas Gauthier
    Nicholas Short
    Sarah Bonnet
    Koji Sasaki
    Sabine Khalife-Hachem
    Mahesh Swaminathan
    Jean-Baptiste Micol
    Florence Pasquier
    Christophe Marzac
    Damien Roos-Weil
    Laurent Pascal
    Naval Daver
    Tapan Kadia
    Didier Bouscary
    Farhad Ravandi
    Arnaud Pages
    Hagop Kantarjian
    Stéphane De Botton
    Courtney DiNardo
    Blood Cancer Journal, 15 (1)
  • [46] Antifungal Prophylaxis in the Treatment Combination of Hypomethylating Agents and Venetoclax for AML: A Survey Study of the Turkish Society of Hematology Subcommittee on Infections and Supportive Therapies in Hematology
    Kirkizlar, Tugcan Alp
    Ozkocaman, Vildan
    TURKISH JOURNAL OF HEMATOLOGY, 2025, 42 (01) : 69 - 71
  • [47] Dismal survival outcomes of patients with acute myeloid leukemia after failure of venetoclax with hypomethylating agents
    Zainaldin, Carl
    Arora, Sankalp
    Bathini, Srilakshmi
    Gupta, Udita
    Pandya, Vishruti
    Bae, Sejong
    Worth, Sarah
    Bachiashvili, Kimo
    Bhatia, Ravi
    Godby, Kelly
    Jamy, Omer
    Rangaraju, Sravanti
    Diamond, Barry
    Oliver, Josh D.
    Salzman, Donna
    Di Stasi, Antonio
    Vachhani, Pankit
    LEUKEMIA & LYMPHOMA, 2022, 63 (13) : 3245 - 3248
  • [48] Outcomes of Venetoclax and Hypomethylating Agents (HMA) in Adult Patients with KMT2A-Rearranged Leukemias
    Ball, Brian
    Arslan, Shukaib
    Koller, Paul
    Murata-Collins, Joyce
    Afkhami, Michelle
    Pillai, Raju
    Gaal, Karl
    Salhotra, Amandeep
    Al Malki, Monzr M.
    Aribi, Ahmed
    Ali, Haris
    Otoukesh, Salman
    Amanam, Idoroenyi
    Nakamura, Ryotaro
    Smith, Eileen P.
    Stewart, Forrest
    Marcucci, Guido
    Pullarkat, Vinod A.
    Aldoss, Ibrahim
    BLOOD, 2021, 138
  • [49] Outcomes after venetoclax with hypomethylating agents in myelodysplastic syndromes: a systematic review and meta-analysis
    Khanam, Razwana
    Shahzad, Moazzam
    Chaudhary, Sibgha Gull
    Ali, Fatima
    Shah, Zunairah
    Pachika, Pranali S.
    Ahmed, Zahoor
    Chattaraj, Asmi
    Masood, Adeel
    Ahmed, Nausheen
    Bansal, Rajat
    Balusu, Ramesh
    Shune, Leyla
    Anwar, Faiz
    Hematti, Peiman
    McGuirk, Joseph P.
    Yacoub, Abdulraheem
    Mushtaq, Muhammad Umair
    LEUKEMIA & LYMPHOMA, 2022, 63 (11) : 2671 - 2678
  • [50] Outcomes of Venetoclax-Based Regimens Compared with Hypomethylating Agents (HMA) Alone or 7+3 in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia (AML): A Single Center Retrospective Analysis
    Pandey, Manu
    Swaminathan, Mahesh
    Griffiths, Elizabeth A.
    Thompson, James E.
    Przespolewski, Amanda
    Thota, Swapna
    Baron, Jeffrey
    Cronin, Tara L.
    Wang, Eunice S.
    BLOOD, 2019, 134
12345